Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide

Merck KGaA CFO  Matthias Zachert, who helped engineer a cost-cutting drive, is leaving for the top job at his former employer. News of his departure triggered a stock slide of more than 12%.

Former investment banker tapped as new Shire chairwoman

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Shire taps ex-investment banker Susan Kilsby to chair its board

There's movement at the top of Shire. With CEO Flemming Ornskov about a year into his job, the specialty drugmaker has tapped Susan Kilsby to be its new chairman. She will replace Matthew Emmens, Shire's former CEO and chairman since 2008, who is retiring.

Under investor pressure, Teva chairman pledges a smaller, more experienced board

It looks as if Teva Pharmaceutical Industries is taking its shareholders' concerns to heart. Just a few weeks after activist investor Benny Landa rallied support for a boardroom overhaul, Teva has promised to effect some changes: namely, cutting down the size of the board while upping the experience level.

Vivus commercial chief takes a hike after slew of exec exits

Since bungling the launch of obesity drug Qsymia, Vivus has lost more than half its board, its CFO, two CEOs and 20 staffers. Now, the company's chief commercial officer is following his departed colleagues out the door.

Novartis oncology chief Hoppenot exits to helm Incyte

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review

Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial public offering for its IT subsidiary, NNIT, and has hired a new CFO for the unit to handle the review.

Roche picks a new R&D boss as Barron ships out for Google

Roche didn't waste much time in replacing former R&D guru Hal Barron, tapping oncology head Sandra Horning to serve as its next chief medical officer and head of global product development.

Novartis Oncology chief Hoppenot leaps to the CEO job at partner Incyte

Novartis is saying goodbye to the man who steered its cancer business. Hervé Hoppenot, president of Novartis Oncology, has jumped ship for the CEO job at Incyte, one of the Swiss drugmaker's longtime development partners.

C-suite shuffle: Amgen CFO Peacock resigns

The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis.